469 related articles for article (PubMed ID: 17363589)
1. Histone H2AX is a mediator of gastrointestinal stromal tumor cell apoptosis following treatment with imatinib mesylate.
Liu Y; Tseng M; Perdreau SA; Rossi F; Antonescu C; Besmer P; Fletcher JA; Duensing S; Duensing A
Cancer Res; 2007 Mar; 67(6):2685-92. PubMed ID: 17363589
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of the kinase inhibitor SU11248 against gastrointestinal stromal tumor mutants refractory to imatinib mesylate.
Prenen H; Cools J; Mentens N; Folens C; Sciot R; Schöffski P; Van Oosterom A; Marynen P; Debiec-Rychter M
Clin Cancer Res; 2006 Apr; 12(8):2622-7. PubMed ID: 16638875
[TBL] [Abstract][Full Text] [Related]
3. Imatinib mesylate: in the treatment of gastrointestinal stromal tumours.
Croom KF; Perry CM
Drugs; 2003; 63(5):513-22; discussion 523-4. PubMed ID: 12600228
[TBL] [Abstract][Full Text] [Related]
4. Proapoptotic activity of bortezomib in gastrointestinal stromal tumor cells.
Bauer S; Parry JA; Mühlenberg T; Brown MF; Seneviratne D; Chatterjee P; Chin A; Rubin BP; Kuan SF; Fletcher JA; Duensing S; Duensing A
Cancer Res; 2010 Jan; 70(1):150-9. PubMed ID: 20028860
[TBL] [Abstract][Full Text] [Related]
5. Flavopiridol targets c-KIT transcription and induces apoptosis in gastrointestinal stromal tumor cells.
Sambol EB; Ambrosini G; Geha RC; Kennealey PT; Decarolis P; O'connor R; Wu YV; Motwani M; Chen JH; Schwartz GK; Singer S
Cancer Res; 2006 Jun; 66(11):5858-66. PubMed ID: 16740725
[TBL] [Abstract][Full Text] [Related]
6. Role for the proapoptotic factor BIM in mediating imatinib-induced apoptosis in a c-KIT-dependent gastrointestinal stromal tumor cell line.
Gordon PM; Fisher DE
J Biol Chem; 2010 May; 285(19):14109-14. PubMed ID: 20231287
[TBL] [Abstract][Full Text] [Related]
7. Activating mutations in c-KIT and PDGFRalpha are exclusively found in gastrointestinal stromal tumors and not in other tumors overexpressing these imatinib mesylate target genes.
Burger H; den Bakker MA; Kros JM; van Tol H; de Bruin AM; Oosterhuis W; van den Ingh HF; van der Harst E; de Schipper HP; Wiemer EA; Nooter K
Cancer Biol Ther; 2005 Nov; 4(11):1270-4. PubMed ID: 16294026
[TBL] [Abstract][Full Text] [Related]
8. Gastrointestinal stromal tumors.
Antonescu C
Curr Top Microbiol Immunol; 2012; 355():41-57. PubMed ID: 22015552
[TBL] [Abstract][Full Text] [Related]
9. Platelet-Derived Growth Factor Receptor-α Regulates Proliferation of Gastrointestinal Stromal Tumor Cells With Mutations in KIT by Stabilizing ETV1.
Hayashi Y; Bardsley MR; Toyomasu Y; Milosavljevic S; Gajdos GB; Choi KM; Reid-Lombardo KM; Kendrick ML; Bingener-Casey J; Tang CM; Sicklick JK; Gibbons SJ; Farrugia G; Taguchi T; Gupta A; Rubin BP; Fletcher JA; Ramachandran A; Ordog T
Gastroenterology; 2015 Aug; 149(2):420-32.e16. PubMed ID: 25865047
[TBL] [Abstract][Full Text] [Related]
10. Kitlow stem cells cause resistance to Kit/platelet-derived growth factor alpha inhibitors in murine gastrointestinal stromal tumors.
Bardsley MR; Horváth VJ; Asuzu DT; Lorincz A; Redelman D; Hayashi Y; Popko LN; Young DL; Lomberk GA; Urrutia RA; Farrugia G; Rubin BP; Ordog T
Gastroenterology; 2010 Sep; 139(3):942-52. PubMed ID: 20621681
[TBL] [Abstract][Full Text] [Related]
11. A novel tyrosine kinase switch is a mechanism of imatinib resistance in gastrointestinal stromal tumors.
Mahadevan D; Cooke L; Riley C; Swart R; Simons B; Della Croce K; Wisner L; Iorio M; Shakalya K; Garewal H; Nagle R; Bearss D
Oncogene; 2007 Jun; 26(27):3909-19. PubMed ID: 17325667
[TBL] [Abstract][Full Text] [Related]
12. Molecular research directions in the management of gastrointestinal stromal tumors.
Tarn C; Godwin AK
Curr Treat Options Oncol; 2005 Nov; 6(6):473-86. PubMed ID: 16242052
[TBL] [Abstract][Full Text] [Related]
13. Silencing of adaptor protein SH3BP2 reduces KIT/PDGFRA receptors expression and impairs gastrointestinal stromal tumors growth.
Serrano-Candelas E; Ainsua-Enrich E; Navinés-Ferrer A; Rodrigues P; García-Valverde A; Bazzocco S; Macaya I; Arribas J; Serrano C; Sayós J; Arango D; Martin M
Mol Oncol; 2018 Aug; 12(8):1383-1397. PubMed ID: 29885053
[TBL] [Abstract][Full Text] [Related]
14. Opposing roles of KIT and ABL1 in the therapeutic response of gastrointestinal stromal tumor (GIST) cells to imatinib mesylate.
Rausch JL; Boichuk S; Ali AA; Patil SS; Liu L; Lee DM; Brown MF; Makielski KR; Liu Y; Taguchi T; Kuan SF; Duensing A
Oncotarget; 2017 Jan; 8(3):4471-4483. PubMed ID: 27965460
[TBL] [Abstract][Full Text] [Related]
15. High CD133 expression levels in gastrointestinal stromal tumors.
Bozzi F; Conca E; Manenti G; Negri T; Brich S; Gronchi A; Pierotti MA; Tamborini E; Pilotti S
Cytometry B Clin Cytom; 2011; 80(4):238-47. PubMed ID: 21462307
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic effect of imatinib in gastrointestinal stromal tumors: AKT signaling dependent and independent mechanisms.
Tarn C; Skorobogatko YV; Taguchi T; Eisenberg B; von Mehren M; Godwin AK
Cancer Res; 2006 May; 66(10):5477-86. PubMed ID: 16707477
[TBL] [Abstract][Full Text] [Related]
17. Pharmacological Inhibition of KIT Activates MET Signaling in Gastrointestinal Stromal Tumors.
Cohen NA; Zeng S; Seifert AM; Kim TS; Sorenson EC; Greer JB; Beckman MJ; Santamaria-Barria JA; Crawley MH; Green BL; Rossi F; Besmer P; Antonescu CR; DeMatteo RP
Cancer Res; 2015 May; 75(10):2061-70. PubMed ID: 25836719
[TBL] [Abstract][Full Text] [Related]
18. Resistance to c-KIT kinase inhibitors conferred by V654A mutation.
Roberts KG; Odell AF; Byrnes EM; Baleato RM; Griffith R; Lyons AB; Ashman LK
Mol Cancer Ther; 2007 Mar; 6(3):1159-66. PubMed ID: 17363509
[TBL] [Abstract][Full Text] [Related]
19. Oncogenic Kit signaling and therapeutic intervention in a mouse model of gastrointestinal stromal tumor.
Rossi F; Ehlers I; Agosti V; Socci ND; Viale A; Sommer G; Yozgat Y; Manova K; Antonescu CR; Besmer P
Proc Natl Acad Sci U S A; 2006 Aug; 103(34):12843-8. PubMed ID: 16908864
[TBL] [Abstract][Full Text] [Related]
20. Identification and treatment of chemoresistant inoperable or metastatic GIST: experience with the selective tyrosine kinase inhibitor imatinib mesylate (STI571).
Demetri GD
Eur J Cancer; 2002 Sep; 38 Suppl 5():S52-9. PubMed ID: 12528773
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
